• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Isobutyl iodide
4-Bromo-1-butene
Paradol
Oligopeptide - 1
Acalabrutinib 1420477-60-6 High Quality and Competitive Price for API
High Quality Unii-4u07f515LG / Eltrombopag Olamine / CAS 496775-62-3

Biocon launches Tacrolimus capsules in US

expresspharmaDecember 29, 2020

Tag: Biocon , Tacrolimus Capsules , US , immunosuppressant , Organ transplant

Biocon announced the launch of Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ.

It has been particularly effective in treating patients of renal transplant for more than two decades.

Siddharth Mittal, CEO and MD, Biocon, said, “The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects our commitment to continually evaluate and expand our portfolio of complex products to serve patients.”


Previous:LYNPARZA (olaparib) get three new approvals in Japan

Next:Serum Institute of India launches indigenously developed pneumococcal vaccine, ‘PNEUMOSIL’

Related News

Olympus Launches New 4K Camera Head for Urological Endoscopy

PharmaSourcesSeptember 24, 2024

Unified Visualization with True 4K Imaging and 4K Narrow Band Imaging as well as blue light observation

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Biocon launches Tacrolimus capsules in US | Pharmasources.com

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.

You may like
More>>

Ferrous gluconate

Ferrous gluconate
Sulfamide USP supplier API Pharmaceutical Sulfanilamide made in china

Sulfamide USP supplier API Pharmaceutical Sulfanilamide made in china
Ferrous fumarate

Ferrous fumarate
  Citric Acid Anhydrous

  Citric Acid Anhydrous
chilli extract hibiscus flower extract

chilli extract hibiscus flower extract

Food Additive Grade Copper Gluconate Anhydrous Powder 527-09-3 Copper Gluconate

Food Additive Grade Copper Gluconate Anhydrous Powder 527-09-3 Copper Gluconate
Praziquantel API USP

Praziquantel API USP
β- Carotene Suspension 30%

β- Carotene Suspension 30%
Bulk Food Grade Jerusalem Artichoke Water Soluble Jerusalem Artichoke Extract Powder 90% Inulin

Bulk Food Grade Jerusalem Artichoke Water Soluble Jerusalem Artichoke Extract Powder 90% Inulin
Obtuseleaf Senna Seed Extract, Semen Cassiae Extract

Obtuseleaf Senna Seed Extract, Semen Cassiae Extract

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service